Exclusive Summary

• Utilizes the proprietary GalAhead/mxRNA platform, featuring a single-stranded oligonucleotide structure that simplifies CMC processes and strengthens IP protection.
• Demonstrated superior duration and potency in Non-Human Primates (NHP) head-to-head studies at a lower dose (3mg/kg) compared to the clinical-stage competitor Arrowhead's ARO-ApoC3 (4mg/kg).
• Targets the validated ApoC3 pathway for Hypertriglyceridemia, offering a potential Best-in-Class profile with long-acting efficacy to reduce cardiovascular and pancreatitis risks.

Asset Materials

Contact Us for Full Materials